CRISPR Therapeutics AG (CRSP)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 892 | 865 | 602 | |
| Research and development | 69,894 | 72,484 | 82,160 | |
| General and administrative | 18,916 | 19,296 | 17,419 | |
| Collaboration expense, net | 45,153 | 57,509 | 11,153 | |
| Acquired in-process research and development | 96,253 | - | - | |
| Total operating expenses | 230,216 | 149,289 | 110,732 | |
| Loss from operations | -229,324 | -148,424 | -110,130 | |
| Other income, net | 22,067 | 13,537 | 25,064 | |
| Total other income, net | 22,067 | 13,537 | 25,064 | |
| Net loss before income taxes | -207,257 | -134,887 | -85,066 | |
| Provision for income taxes | 1,292 | 1,109 | 876 | |
| Net loss | -208,549 | -135,996 | -85,942 | |
| Foreign currency translation adjustment | 80 | 41 | 76 | |
| Unrealized (loss) gain on marketable securities | -174 | 2,254 | 13,368 | |
| Comprehensive loss | -208,643 | -133,701 | -72,498 | |
| Basic net (loss) income per common share | -2.4 | -1.58 | -1.01 | |
| Diluted net (loss) income per common share | -2.4 | -1.58 | -1.01 | |
| Weighted average number of shares outstanding, basic, total | 87,069,690 | 85,938,720 | 85,234,926 | |
| Weighted average number of shares outstanding, diluted | 87,069,690 | 85,938,720 | 85,234,926 | |